Clinical Trials

30 enrolled

Prostatic Neoplasms

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT07468903 2026-05-22

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Phase NA Recruiting

45 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

132 enrolled 22 charts

Prostatic Neoplasms

NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled 10 charts

Prostatic Neoplasms

NCT06733350 2026-05-14

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Recruiting

600 enrolled

Prostatic Neoplasms

NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05828082 2026-05-13

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

20 enrolled

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

24 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT06995898 2026-05-13

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05689021 2026-05-11

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT04134260 2026-05-07

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

586 enrolled

Prostatic Neoplasms

NCT05946213 2026-05-07

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Phase 3 Recruiting

1,209 enrolled

Prostatic Neoplasms

NCT06616155 2026-05-05

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

20 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT05053152 2026-05-04

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

194 enrolled

Prostatic Neoplasms

NCT04530552 2026-04-23

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

34 enrolled 11 charts

Prostatic Neoplasms

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Prostatic Neoplasms

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

30 enrolled

Prostatic Neoplasms

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

8 enrolled

Prostatic Neoplasms

NCT06389786 2026-04-06

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Phase NA Recruiting

50 enrolled

Prostatic Neoplasms

NCT06526299 2026-03-24

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

51 enrolled